Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab versus secukinumab and placebo in moderate-to-severe plaque psoriasis
2017-003286-10Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mirikizumab, secukinumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Mar 2018; status: completed.
02
Drugs
mirikizumabsecukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2017-003286-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003286-10.